Pharmacogenomic Testing: Clinical Trials

25 trials of Pharmacogenomic Testing, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 5 terminated, 3 active not recruiting. 25 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 125Completed 17, Terminated 5, Active not recruiting 3
Phase 23Completed 2, Active not recruiting 1

Follow Pharmacogenomic Testing: new trials by email Literature Review of Pharmacogenomic Testing trials Research Report on Pharmacogenomic Testing

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
Biopsy Procedure, Blood Sample, Bone Scan - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1Active not recruitingNational Cancer Institute (NCI)572016-02-122026-11-18
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Phase 1Active not recruitingKami Maddocks, MD482014-03-262026-07-22
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study - BRAF Gene Mutation, Hepatic Complication
Phase 1TerminatedNational Cancer Institute (NCI)82013-08-232018-08-14
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
dabrafenib, pazopanib hydrochloride, Correlative studies - Unspecified Adult Solid Tumor, Protocol Specific
Phase 1CompletedManisha Shah232012-11-192019-03-01
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
capecitabine, celecoxib, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific
Phase 1TerminatedUniversity of Chicago212012-08-292018-05-30
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride - Leydig Cell Tumor, Ovarian Sarcoma
Phase 1CompletedCase Comprehensive Cancer Center122012-05-012015-08-04
Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy
Pharmacogenomics testing for clopidogrel responsiveness - Stroke, Transient Ischemic Attack
Phase 1CompletedUniversity of North Carolina, Chapel Hill482011-12-012012-06-08
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase 1CompletedUniversity of Washington132011-06-012015-03-05
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate - Estrogen Receptor Negative, Estrogen Receptor Positive
Phase 1TerminatedNational Cancer Institute (NCI)42011-01-012015-08-27
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
carfilzomib, Cytokine Assessment, Pharmacodynamic Studies - B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer
Phase 1CompletedOhio State University Comprehensive Cancer Center212010-10-012016-05-09
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
pralatrexate, fluorouracil, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific
Phase 1CompletedUniversity of Nebraska292010-09-142023-12-26
Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma
Cilengitide dose escalation, Cilengitide, Concomitant radiotherapy - Diffuse Intrinsic Pontine Glioma
Phase 1CompletedCentre Oscar Lambret322010-09-062026-03-16
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Phase 1CompletedAmir Mortazavi442010-05-042018-06-04
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
alvespimycin hydrochloride, diagnostic laboratory biomarker analysis, pharmacogenomic studies - B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia
Phase 1TerminatedNational Cancer Institute (NCI)302010-05-012015-11-04
Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies
gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacogenomic studies - Unspecified Adult Solid Tumor, Protocol Specific
Phase 1CompletedNational Cancer Institute (NCI)282010-02-012014-04-02
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study - Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)882009-11-032026-09-14
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study - Estrogen Receptor Negative, HER2/Neu Negative
Phase 1TerminatedNational Cancer Institute (NCI)132009-11-012015-04-15
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
sorafenib tosylate, everolimus, laboratory biomarker analysis - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Phase 1CompletedRoswell Park Cancer Institute122009-08-012022-09-13
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
temozolomide, veliparib, DNA methylation analysis - Brain and Central Nervous System Tumors
Phase 1CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins242009-07-132018-06-27
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)122009-07-012014-01-07

Showing 20 of 25. Sign in to see all of them.

Conditions studied

Breast Neoplasms (4)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (4)  ·  Leukemia, Prolymphocytic (3)  ·  Lymphoma, B-Cell, Marginal Zone (3)  ·  Lymphoma, Follicular (3)  ·  Lymphoma, Large B-Cell, Diffuse (3)  ·  Lymphoma, Mantle-Cell (3)  ·  Waldenstrom Macroglobulinemia (3)  ·  Burkitt Lymphoma (2)  ·  Carcinoma, Ovarian Epithelial (2)  ·  Fallopian Tube Neoplasms (2)  ·  Hodgkin Disease (2)  ·  Immunoblastic Lymphadenopathy (2)  ·  Lymphoma, Extranodal NK-T-Cell (2)  ·  Lymphoma, Large-Cell, Anaplastic (2)

Sponsors

National Cancer Institute (NCI) (9)  ·  Amir Mortazavi (1)  ·  Cancer Research UK (1)  ·  Case Comprehensive Cancer Center (1)  ·  Centre Oscar Lambret (1)  ·  City of Hope Medical Center (1)  ·  Kami Maddocks, MD (1)  ·  Manisha Shah (1)  ·  Mayo Clinic (1)  ·  National Cancer Centre, Singapore (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  Roswell Park Cancer Institute (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  University of Chicago (1)  ·  University of Nebraska (1)

Countries

United States (21)  ·  Canada (2)  ·  France (1)  ·  Singapore (1)  ·  United Kingdom (1)

Top investigators

Patricia LoRusso (3)  ·  Amir Mortazavi, MD (1)  ·  Andrea E Wahner Hendrickson (1)  ·  Charles Rudin (1)  ·  Jean Grem (1)  ·  Jeffrey Jones (1)  ·  Jennifer Woyach, MD (1)  ·  Johann Sebastian de Bono, MD (1)  ·  Kami Maddocks, MD (1)  ·  Larry Kleinberg, MD (1)  ·  Laura Chow (1)  ·  Lillian Siu (1)  ·  Manish R. Sharma, M.D. (1)  ·  Manisha Shah, MD (1)

Results publications

PMID 25355819, PMID 26242208, PMID 26928328, PMID 26943915, PMID 28270022, PMID 28654574, PMID 30181415, PMID 33492438

NIH funding

P30CA022453 (3), U01CA062487 (3), P30CA015083 (2), P30CA016058 (2), U01CA062490 (2), U01CA069912 (2), U01CA070095 (2), U01CA132123 (2), UM1CA186686 (2), UM1CA186690 (2), UM1CA186691 (2), UM1CA186717 (2), 2009 (1), P30CA015704 (1), P30CA033572 (1)